Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. [PDF]
PLoS ONE, 2013 Emergence of resistance to Tyrosine-Kinase Inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, in Chronic Myelogenous Leukemia (CML) demands new therapeutic strategies.
Octavian Bucur +7 more
doaj +1 more source
Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia [PDF]
Leukemia, 2001 To investigate the mechanisms behind the leukemic expansion of BCR/ABL-positive chronic myelogenous leukemia (CML), we examined the cell cycle status of hematopoietic progenitor cells from peripheral blood (PB) and bone marrow (BM) of 37 patients with newly diagnosed BCR/ABL-positive CML.
A, Krämer +4 more
openaire +2 more sources
Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) chimeric transcripts [PDF]
Precision and Future Medicine, 2019 Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with the molecular hallmark of BCR-ABL1 chimeric transcripts from t(9;22)(q24;q22). In more than 95% of CML, the fusion occurs in the major breakpoint cluster region (M-bcr) of BCR, most ...
Jae Won Yun +5 more
doaj +1 more source
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice [PDF]
Leukemia, 2011 Although BCR-ABL+ stem cells in chronic myeloid leukemia (CML) resist elimination by targeted pharmacotherapy in most patients, immunological graft-versus-leukemia effects can cure the disease. Besides cytotoxic T cells, natural killer (NK) cells may have a role in immune control of CML.
C I-U, Chen +11 more
openaire +2 more sources
Leukemic infiltration of the ovary as an initial presentation of chronic myeloid leukemia in chronic phase [PDF]
Vojnosanitetski Pregled, 2022 Introduction. Extramedullary sites of leukemic proliferation, harboring an adverse outcome, are rare and usually found in the blastic phase of chronic myeloid leukemia.
Sekulić Borivoj +4 more
doaj +1 more source
Hematology, Transfusion and Cell Therapy, 2022 Introduction: Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success.
Carla Boquimpani +8 more
doaj +1 more source
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Pharmacological Research, 2022 Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that accounts for about 15% of all cases of leukemia. This disorder results from the formation of the Philadelphia chromosome that involves a reciprocal translocation that produces a lengthened chromosome 9 and shortened chromosome 22 - the Philadelphia chromosome.
openaire +2 more sources
The Relationship Between the Type of bcr-abl Hybrid Messenger RNA and Thrombopoiesis in Philadelphia-Positive Chronic Myelogenous Leukemia [PDF]
Leukemia & Lymphoma, 1993 Formation of the Philadelphia (Ph1) chromosome, which contains the hybrid bcr-abl gene, is thought to be the initial event in chronic myelogenous leukemia (CML). The positions of the breakpoint within the breakpoint cluster region (bcr) on the bcr-abl gene in 22 chronic-phase cases of Ph1-positive CML were determined using conventional Southern blots ...
K, Inokuchi, T, Nomura
+8 more sources
The Profile of BCR-ABL1 Fusion Gene in Childhood Leukemia at “Dharmais” Cancer Hospital
Indonesian Journal of Cancer, 2020 Background: BCR-ABL1 fusion gene, which originated from t (9;22), is an important biomarker for diagnosis, therapeutic approach, and prognosis in childhood leukemia.
Mururul Aisyi +7 more
doaj +1 more source
Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1. [PDF]
PLoS ONE, 2015 Constitutively active BCR-ABL kinase fusions are causative mutations in the pathogenesis of hematopoietic neoplasias including chronic myelogenous leukemia (CML).
Pamela Y Ting +12 more
doaj +1 more source